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during the obsemation period of 30 w&s alter PTCk lhkgmfd.
Uafractionated hepariu and its low molecular weight fkagments possess rntiproliferative elerts and bave been showntomhcenmintlmalsnmoUtmuseleceUmigotioaand pmlilwPtlonlnN!spMsetovascaku~ln~tdstndks h&h&. The REDUCE trial is an international prospective, randomized, double-blind, multicenter study. Twenty-six centers in Eumpe and Canada enmlled 625 patients rvilh single-lesion comnay altely obsmctions sultabk tbr PTCA The knndltd six patlents received K!viparin as a 7,~u bdus beeore tW#& foRowed by lO,!%O U as an infiudon over 24 h and then twicedaily 3$00-U snbcutaa4~s application for 28 days. I%e 306 patients in the control gmup received a bolus of lO,WO U of unfractionrted hepario followed by an inf'usioo of 24,000 U over 24 h. These patients then undenrent 28 days of subcutall~~ll~ placebo injections. The primary end points welp eSiaq (defined as a reduction
Resuhs. Using the intention to treat analysis for all patients. 102 (33.3%) in tbe reviparin group and 98 (32%) in the control group have rracbed a primary clinical end point (Rlative risk [RR] 1.04,95% conthlence intemal ICI] 0.83 to 131. p = 0.707). Likewise, no dilerence in late loss of minimal lumen diameter was evident for both groups. Acute events within 24 h oceuned in I2 p&W (3.9%) in the reviparin gmup and 25 (8.2%) in the control gmup (RR 0.49, 95% Cl 0.26 10 0.92. p = 0.027) during or immediately after the initial pmcedure. lo the control group. eight major bleeding complications occurrod, and in the mviparin group, seven were observed within 35 days after PITA.
Cunc/i~~ians. Reviparin use during and after coronary angioplasly did not lPduce the occulTence of mqjor clinical events or the incidence of angiographic restenosis over 30 weeks. rience and rapid advances in tcchnoloby have resulted in a primary success rate of up to 95%. However. late restenosis, which constitutes the most important problem after successful angioplasty. continues to occur in 308 to 50% of patients within 3 to 6 months (2-5). Experimental and human postmortern studies have shown (6.7) that the process of restenosis is at least in ,part due to neointimal proliferation. Although the incidence, timing, clinical. anatomic and pathophysiologic factors associated with restenosis have been studied in depth (g-14) . rtjost medical attempts to reduce the occurrence of restenosis thus far have failed.
Unfraitionated
heparin has long been known as an effective anticoagulani with inhibitory action on platelet function and an additional effect on smooth muscle cell proliferation.
In recent years, low molecular weight heparins have been developed and have been shown to be as etTective and safer than unfractionated heparin in the prevention and treatment of venous thromboembolism (15, 16) . Reviparin is a new low molecular weight heparin with anticoagulatory efficacy comparable to unfractionated heparin and a better safety profile than unfractionated heparin (3.18). In vitro studies with reviparin have shown significant inhibition of smooth muscle cell migration and proliferation in human cell cultures without affecting endothelial cell growth (19). Experimental studies in New Zealand rabbits (20) revealed that the extent of intimal mitosis during the first 7 days after PTCA was significantly reduced (p < 0.01 at 3 days; p < 0.0s a! 7 days) after injections of reviparin (2.5 mg/kg body weight per day subcutaneously, ivhich corresponds to 400 anti-Xa U/kg per day), resulting in only a moderate increase in intimal wall thickness after 28 days compared with that in a control group treated with unfractionated heparin. In a pishminary open clinical pilot trial conducted to evaluate the safety of reviparin application in the clinical setting, no increased bleeding complications were observed (21).
The purpose of the randomized. double blind, placebocontrolled, multicenter REDUCE trial (Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind, Unfractionated Heparin and Placeb&ontrolled Evaluation) was to evaluate whether reviparin given intraarterially and intravenously during PICA and subsequently subcutaneously twice daily for 28 days after PTCA in a dosage equivalent to that used in the animal experiments (211) and compared with unfractionated heparin and placebo would reduce the incidence of restenosis, as determined by the occurrence of major clinical events and angiography. Study protocol. Standard balloon angioplasty was performed through the transfemoral approach using an 8F guide catheter according to standard techniques. At the time of arterial access. either a bolus of unfractionated heparin (10,000 IV) or reviparin (7,ooU IU anti% U) was injected into the femoral sheath. Subsequently, all patients received an intravenous infusion of either unfractionated heparin (24,Wl IU) or reviparin (10,500 IU anti-Xa U) over 16 2 4 h (mean + SD). Aspirin (100 mgiday) was administered 1 day before and throughout the treatment period. Beginning on the evening of day 1. either 3,500 IU anti-Xa U oi reviparin or placebo was administered subcutaneously twice daily for 28 days.
Methods
The clinical follow-up visit was scheduled 4 and 30 weeks after angioplasty for clinical and laboratory assessment. Lahoratory assessment included complete blood count, coagulation profile and liver function tests. The global clotting tests (activated prothrombin time, thromboplastin time end anti-Xa plasma level) were analyzed at core laboratory (Sainte Marie, Paris, France for the European centers; McMaster University Medical Center, Hamilton, Ontario for the Canadian centers). Patient compliance with regard to subcutaneous injections was assessed by a paticr,t booklet to be filled out and the measured anticoagulation levels after 28 days. To assess angiographic restenosis, repeat coronary angiography was performed at 26 2 2 weeks after PICA through the femoral sheath with a 7F femoral diagnostic catheter after readjustment of the X-ray gantry angular settings and the various height levels, according to values previously documented during the original intervention.
The angiograms were sent to the core angiographic laboratory for further blinded analysis. To standardize the method of data acquisition and to ensure the exact reproducibility of the angiograms acquired after intervention and follow-up, measurements were made using the Coronary Artery Analysis System, as 'described elsewhere (22). Ten ,percent of the ingiograms w&e reanalyzed in blinded mannkr as part of the quality control assessment.
Study fad points. The.pimary clinical end point was defined as the first occurrence of any of the following events in the first 30 weeks after the initial procedure: death from any cause; nonfatal myocardial infarction; clinically driven repeat hfyxatdial infarction was defined as documented elevation of serum creatine kinase levels to greater than twice the upper limit of normal for the laboratory; electrocardiographic changes indicative of myocardial infarction; o: typical angina1 pain at rest prolonged for >30 min despite administration of nitroglycerin.
The prinwry angiograp/~ic end point was defined in terms of absolute loss in minimal lumen diameter at the diiated site from after IWA to follow-up an;iography (median fo,low-up of 184 days after FTCA) assessed by quantitative coronary analysis. Restenosis was defined as loss of >504 of the initial gain of PTCA, according to the National Heart. Lung, and Blood Institute (NHLBI) 4 definition.
The safety of the trial medication and the feasibility of replacing standard heparin during the intervention was assessed in terms of occurrence of bleeding complications or other adverse events that could be attributed to the trial medication. In addition, bleeding was quantified as major or minor. Major bleeding was defined as a clinically evident bleeding episode associated with a decrease in hemoglobin of al least 2 g/dl or requiring transfusion of at least 2 U of blood. or both. Any intracerebral or retroperitoneal bleeding was considered a major episode. The site and source of bleeding episodes were noted. D&I Nt and statIstIcal snaIpis. The primary variable for biometric clinical evaluation was the incidence of clinical events. as previously already defined. On the basis of data from previous trials (23). this trial was planned to include a minimum of 281 patients/group to detect a reduction of 40% in the primaty clinical end point (the event rate in the control group was predicted to be 30%. with alpha = 0.05. beta = 0.1 The results of the two treatment groups were displayed as Kaplan-Meier survival curves (24). For the primary end point, a Mantel-Haenszel test was performed using the end point rates in the two treatment groups until the end of week 30. This analysis involved all randomized patients with the exception of I3 patients who did not receive study medication, according to the intention to treat principle. The primary angiographic end point was statistically evaluated by comparison between the two treatment groups with respect to loss of minimal lumen diameter from after PTCA to the 26 tieek follow-up visit and was performed according to the intention to treat principle for 
Results
The intention to treat patient group included all patients who received at least one dose of the study medication. The clinical "per protocol" paricnt group included all compliant patients of the intention to treat clinical cohort who had an initial single-vessel single-lesion FTCA and a complete clinical follow-up. Three hundred six patients were randomized to receive unfractionared heparin/placebo and 306 to receive reviparin. Clinical or telephone follow-up for evaluation of the primary clinical end point was obtained for 601 patients. During the course of the study. eight patients were lost to follow-up, and three had their second follow-up visit before the end of week 30. and no telephone evaluation of the end point Was obtained. The +aseiitie characteristics of the intention to treat cohort are given in Tables I and 2 . The two treatment groups did not differ III sny baseline clinical or angiographic characteristics. In general, patients had one-vessel disease. and a single lesion was dilated in all patients according to the inclusion criteria. Comparison of baseline characteristics in the per protocol patient group also showed, no dilIerence in any baaline characteristic. Ninety-three patients in the control group and 7Y in the reviparin group were excluded from the per protocol analysis. The primary reason for exclusion was insuficient compliance with the 6-month follow-up visit or missing protocol compliance. Nineteen patients did not meet entry criteria (Table 3 ). The mean dose of intravenous infusion was 92.164 for the control group and 93.05G for the reviparin group. Comparable compliance was observed for the administration of the subcutaneous injections.
Primary dicacy analysis. Using the intention to treat analysis (Table 4) . treatment failure, as defined by the occurrence of death, myocardial infarction. bypass surgery and emergency or elective repeat PTCA in the observation per&f. was 33.3% for the rcviparin group and 32% for the control group (relative risk [RR] 1.04, 95% confidence interval [Cl] 0.83 to 1.31. p = 0.707) ( Table 4) . Angiographic restenasis using the NHLBI 4 definition was present in H6 (.34.4'1;,) patients m the control group and in 89 (33%) in the reviparin group. Only 61 (19.9%) patients in the control group and 5U (16.4%) in the reviparin group developed significant angina requiring repeat coronary angiophsty. indicating that a certain percentage of patients had aymptcmatic restenosis. The occurrence of death and myocardial irlfarction was an infrequent event (2.6% in the control group [13 patients] and 4.5% [8 patients] in the reviparin group). Subsequent revascularization with bypass surgery or angioplasty was performed in 69 (22.6%,) of the patients in the control group and in 81(26.8%1) of the patients in the rcviparin group.
However, acute cvcnls during or immediately after the procedure-(day 1) 'occurred in 12 (3.9%) pati$nts in the reviparin group and in 25 (8.2%) of the control group (RR 0.49,95% Cl 0.26 to 0.92, p = 0.027) (Fig. 1) . Emergency stent implantation in the acute stage was riiffcrent in the two groups (21 patients in the control group vs. 6 in the reviparin group; RR 0.29, 95% Cl 0.13 to 0.66, p = 0.03). Autoperfusion balloons in the event of TIMI perfusion grade 0 or 1 after angioplasty were used in 16 patients in the control group and JACC Vol. X No. 6 Nwcmhcr I!. lWl437-45 Angiogtaphic analysis. The change in minimal lumen and reference diameters before and after PTCA and at the h-month follow-up visit were assessed for all patients in whom follow-up angiography was available (n = 514). The mean acute gain in minimal lumen diameter was 0.84 mm for the control group and 0.88 mm for the reviparin group. The mean late loss in minimal lumen diameter was 0.25 and U.2Y mm. respectively (p = 0.55, analysis of covariance). The cumulative distribution of the minimal lumen diameter before and immediately after FTCA and at follow-up angiography likewise showed no difference between the two groups and followed a gaussian distribution.
Bleeding romplkatlons.
No substantial differences were found in the rate of major bleeding complications: 8 patients (2.6%) in the control group vs. 7 patients (2.3%) in the reviparin group (RR 0.88, 95% CI 0.32 to 2.41, p -0.8). All major bleeding episodes occurred within 35 days after PTCA. There was one episode of intracerrbrsl and one of intraocular bleeding in the reviparin group, and all except rhrec major bleeding episodes in the contml group occurred a1 the femoral arterial entry sheath (Table 5 ).
Discussion
The results of the present study demonstrate that rcviparin did not reduce adverse clinical outcome or the occurrence of angiographic restenosis compared with unfractionated heparin/ placebo over a period of 6 months.
E&cts of heparia and its low decular weight fractions.
Heparin is used routinely during angioplasty to reduce the risk of a thrombotic abrupt vessel closure. However, it is also well Cell culture data demonstrated that the dosedependent antiproliferative properties of low molecular weight heparins are more potent and are basically independent of their ability to bind antithrombin III (29). Although the exact mechanism oi action of heparin and its low molecular weight fractions for prevention of cell proliferation is not fully understood, the antipmliferative effect of heparin and its analogues appears to be due to the inhibition of thymidine and uridinc uptake by smooth muscle cells (26). It is assumed that the glycusaminoglycans provide an important cell regulatory action within the arterial wall (27). Reviparin. a low molecular weight heparin. differs from unfractionatcd hrparin in a numher of ways (30). It is generated from hcparin by chemical depolymerization and has an average molecular weight of 4,300 daltons. The depolymerization process produces widely different products with differences in their microstructure, antithrombin III affinity and the degree of sulfation. Because of the shorter chain length. it has approximately three times more anti-Xa activity than anti-lla activity in contrast to the I:1 ratio for heparin.
Experience with heparins in reducing rpstcnosis. Attsmpts to modify the tihroproliferdlive rrsponse due to angioplasty by pharmacologic interventions have yielded very limited success. Ellis ct al. (31) reported that an 1% to 24-h infusion of heparin after PTCA did not prevent restenosis in a randomized trial. In one study (32) using fragmin, a low molecular weight heparin, a significant trend toward a reduction in restenosis was seen. A p,:eliminary brief report (31) of a randomized trial of lO.ooO U oi subcutaneous heparin once daily compared with placebo kas discontinued because of a high incidence of adverse events and angiographic restenosis. One report (33) has even suggcstcd that hcparin treatment may promote restenosis. Enoxaparin in a dose of 40 mg/day subcutaneously for I mnnth did not reduce the incidence of angiographic restenosis or the occurrence of clinical events over 6 months (-34).
Study tIesIgn. In view of this previous experience. several aspects of the REDUCE trial are noteworthy. The selection of patients with single-lesion dilation was designed to avoid confusion' resulting fmm differences in per patient and per lesion rysults. Patients with restenosis or myocardial infarction within 14 days of PTCA were 'excluded to first define the impact of the substance in a population with comparable pathophysiologic substrates. The pharmacologic regimen was based on similar experimental designs, and the dosage was adjusted according to the dosage that'resulted in a significant reduction of smooth muscle cell proliferation i? the expexi- dosage. without the occurrence of increased bleeding complications. It is of major clinical interest that no monitoring was ncedcd to follow the trcatmcnt with rcviparin. According to the cxperimcntally documented time course of smooth mmsclc ccl1 proliferation after vascular injury (H), a specific delivery protocol was adopted. Rccausc the process of smooth muscle cell proliferation begins with the onset of injury and continues for at lcast 2 weeks. treatment with reviparin was started early and was maintained for a su5icient length of time.
Reasons for lark of benefit. There are many potential reasons for the lack of an effect of reviparin on restenosis: 1) Systemically or subcutaneously injected doses might not have been sufficient to reduce the local arterial proliferative actions. To further svaluate this option. local application with specific local delivery systems (35-37) as well as trials using hcparincoated stems (38) are in the expcrimcntal and early clinical stages.
2) The lack of benefit to date shown in nearly all clinical trials of drugs to prevent restcnosis that previously were shown to be effective in animal models also raises concerns about the validity of the animal models used to study the restenosis process. 3) Chan et al. (39) have found that cells from patients with restenosis (both restenotic lesion and undiseased vessels) showed significant lower sensitivity to growth inhibition by heparin than control cells (p c 0.001). This relative heparin resistance of human vascular smooth muscle cells may explain why pharmacologic agents that inhibit ncointimal proliferation in animal models have failed to prevent human vascular restenosis. In a recent study (40) low molecular weight heparin given in high doses has been ineffective in inhibiting smooth muscle cell proliferation in a baboon model of angioplasty. It is proposed that the lack of an effect in primates might reflect the presence of a heperin-insensitive pathway of smooth muscle cell activation, possibly through platelet-derived growth factor. 4) Rcstcnosis is a multifactorial process, including such factors as vessel recoil and fibrotic contraction, and attempts to prevent it by a single agent focused on a single process may be inadequate.
Acute t~ults. The administration of rcviparin as a bolus and infusion resulted in a 52% reduction in the composite acute event rate, primarily in the need for stent implantation as a rescue procedure and in the usc of autoperfusion balloon catheters. However, this finding must be counted as an additional observation because early events and acute complications of PTCA were not designed as an end point of the study.
The rather low incidence of 3.9%. of early events in the present study is comparable to that found in the Hirudin in a European Restenosis Prevention Trial Versus Heparin Treatment in PTCA Patients (HELVETICA) study (41) . which compared the effects of recombinant hirudin as an adjunctive therapy with angioplasty with placebo. A recent trial using a monoclonal antihdy directed against the platelet glycoprotein WIIa receptor (Evaluation of Ilb/llla Platelet Receptor Antagonist 7E3 in Preventing Ischcmic Complications [EPIC] study [42] ) suggested that platelet thromhrsis plays an important role in the abrupt closure of coronary lesions treated by angioplasty. The positive effect of reviparin on the early adverse outcome after PTCA may be due to improved antithrombotic properties compared with those of standard heparin (11.12).
Conclusions. The ability of reviparin to inhibit vascular smooth muscle growth in vitro and to limit myointimal hypcrplasia in animal models of vascular injury is well documented. However, in the present randomized, controlled study, reviparin given at a very early stage of vascular injury, in dosages equal to those used in the animal studies and administered for a sufficient length of time. did not reduce the incidence of clinical rcstcnosis. Explorativc analysis rcvcaled a 52% reduction in the acute-phase adverse outcome, revealing a diminished need for immediate subsequent coronary revascularization procedures 19. Roth D. LIZ E. Kultivicflc Gcf%~wandzcllcn
